Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Hodgkin Lymphoma Treatment Market by Type (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), By Application (Hospital, Clinic, Research Center) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Hodgkin Lymphoma Treatment Market by Type (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), By Application (Hospital, Clinic, Research Center) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 194992 3300 Pharma & Healthcare 377 243 Pages 4.8 (45)
                                          

The global Hodgkin lymphoma treatment market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing incidence of Hodgkin lymphoma and rising awareness about the disease. The North American region is expected to dominate the global market with a share of over 40%. This can be attributed to high prevalence rates in this region and increasing number of patients diagnosed with Hodgkin lymphoma in this region. -There are many clinical trials for Hodgkin lymphoma treatment that are ongoing or planned to start soon.

Industry Growth Insights published a new data on “Hodgkin Lymphoma Treatment Market”. The research report is titled “Hodgkin Lymphoma Treatment Market research by Types (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), By Applications (Hospital, Clinic, Research Center), By Players/Companies Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis, Inc., Faron Pharmaceuticals Oy, Fate Therapeutics, Inc., Gamida Cell Ltd., Gilead Sciences, Inc., Incyte Corporation, Merck & Co., Inc., Mirati Therapeutics Inc., Molecular Templates Inc., NantKwest, Inc.”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Hodgkin Lymphoma Treatment Market Research Report

By Type

Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others

By Application

Hospital, Clinic, Research Center

By Companies

Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis, Inc., Faron Pharmaceuticals Oy, Fate Therapeutics, Inc., Gamida Cell Ltd., Gilead Sciences, Inc., Incyte Corporation, Merck & Co., Inc., Mirati Therapeutics Inc., Molecular Templates Inc., NantKwest, Inc.

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

243

Number of Tables & Figures

171

Customization Available

Yes, the report can be customized as per your need.


Global Hodgkin Lymphoma Treatment Industry Outlook


Global Hodgkin Lymphoma Treatment Market Report Segments:

The global Hodgkin Lymphoma Treatment market is segmented on the basis of:

Types

Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Clinic, Research Center

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Cell Medica Limited
  2. Cellular Biomedicine Group, Inc.
  3. Constellation Pharmaceuticals, Inc.
  4. Curis, Inc.
  5. Faron Pharmaceuticals Oy
  6. Fate Therapeutics, Inc.
  7. Gamida Cell Ltd.
  8. Gilead Sciences, Inc.
  9. Incyte Corporation
  10. Merck & Co., Inc.
  11. Mirati Therapeutics Inc.
  12. Molecular Templates Inc.
  13. NantKwest, Inc.

Global Hodgkin Lymphoma Treatment Market Overview


Highlights of The Hodgkin Lymphoma Treatment Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Alocrest
    2. ANK Program
    3. Azacitidine
    4. BMS-986016
    5. BPX-501
    6. Others
  1. By Application:

    1. Hospital
    2. Clinic
    3. Research Center
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Hodgkin Lymphoma Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Hodgkin Lymphoma Treatment Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Hodgkin lymphoma is a type of cancer that starts in the lymph nodes. Treatment usually includes chemotherapy and radiation therapy.

Some of the key players operating in the hodgkin lymphoma treatment market are Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis, Inc., Faron Pharmaceuticals Oy, Fate Therapeutics, Inc., Gamida Cell Ltd., Gilead Sciences, Inc., Incyte Corporation, Merck & Co., Inc., Mirati Therapeutics Inc., Molecular Templates Inc., NantKwest, Inc..

The hodgkin lymphoma treatment market is expected to grow at a compound annual growth rate of 5.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Hodgkin Lymphoma Treatment Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Hodgkin Lymphoma Treatment Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Hodgkin Lymphoma Treatment Market - Supply Chain
   4.5. Global Hodgkin Lymphoma Treatment Market Forecast
      4.5.1. Hodgkin Lymphoma Treatment Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Hodgkin Lymphoma Treatment Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Hodgkin Lymphoma Treatment Market Absolute $ Opportunity

5. Global Hodgkin Lymphoma Treatment Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
      5.3.1. Alocrest
      5.3.2. ANK Program
      5.3.3. Azacitidine
      5.3.4. BMS-986016
      5.3.5. BPX-501
      5.3.6. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Hodgkin Lymphoma Treatment Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
      6.3.1. Hospital
      6.3.2. Clinic
      6.3.3. Research Center
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Hodgkin Lymphoma Treatment Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Hodgkin Lymphoma Treatment Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Hodgkin Lymphoma Treatment Demand Share Forecast, 2019-2026

9. North America Hodgkin Lymphoma Treatment Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
      9.4.1. Hospital
      9.4.2. Clinic
      9.4.3. Research Center
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
      9.7.1. Alocrest
      9.7.2. ANK Program
      9.7.3. Azacitidine
      9.7.4. BMS-986016
      9.7.5. BPX-501
      9.7.6. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Hodgkin Lymphoma Treatment Demand Share Forecast, 2019-2026

10. Latin America Hodgkin Lymphoma Treatment Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
      10.4.1. Hospital
      10.4.2. Clinic
      10.4.3. Research Center
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
      10.7.1. Alocrest
      10.7.2. ANK Program
      10.7.3. Azacitidine
      10.7.4. BMS-986016
      10.7.5. BPX-501
      10.7.6. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Hodgkin Lymphoma Treatment Demand Share Forecast, 2019-2026

11. Europe Hodgkin Lymphoma Treatment Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
      11.4.1. Hospital
      11.4.2. Clinic
      11.4.3. Research Center
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
      11.7.1. Alocrest
      11.7.2. ANK Program
      11.7.3. Azacitidine
      11.7.4. BMS-986016
      11.7.5. BPX-501
      11.7.6. Others
   11.8. Basis Point Share (BPS) Analysis byType
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Hodgkin Lymphoma Treatment Demand Share, 2019-2026

12. Asia Pacific Hodgkin Lymphoma Treatment Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
      12.4.1. Hospital
      12.4.2. Clinic
      12.4.3. Research Center
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
      12.7.1. Alocrest
      12.7.2. ANK Program
      12.7.3. Azacitidine
      12.7.4. BMS-986016
      12.7.5. BPX-501
      12.7.6. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Hodgkin Lymphoma Treatment Demand Share, 2019-2026

13. Middle East & Africa Hodgkin Lymphoma Treatment Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
      13.4.1. Hospital
      13.4.2. Clinic
      13.4.3. Research Center
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
      13.7.1. Alocrest
      13.7.2. ANK Program
      13.7.3. Azacitidine
      13.7.4. BMS-986016
      13.7.5. BPX-501
      13.7.6. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Hodgkin Lymphoma Treatment Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Hodgkin Lymphoma Treatment Market: Market Share Analysis
   14.2. Hodgkin Lymphoma Treatment Distributors and Customers
   14.3. Hodgkin Lymphoma Treatment Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Cell Medica Limited
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Cellular Biomedicine Group, Inc.
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Constellation Pharmaceuticals, Inc.
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Curis, Inc.
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Faron Pharmaceuticals Oy
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Fate Therapeutics, Inc.
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Gamida Cell Ltd.
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Gilead Sciences, Inc.
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Incyte Corporation
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Merck & Co., Inc.
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Mirati Therapeutics Inc.
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Molecular Templates Inc.
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. NantKwest, Inc.
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us